Millendo Therapeutics (MLND) Gets a Buy Rating from Oppenheimer

By Carrie Williams

Oppenheimer analyst Jay Olson maintained a Buy rating on Millendo Therapeutics (MLNDResearch Report) today and set a price target of $25.00. The company’s shares closed last Monday at $6.58, close to its 52-week low of $4.56.

According to TipRanks.com, Olson is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -12.2% and a 30.4% success rate. Olson covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, ACADIA Pharmaceuticals, and Enanta Pharmaceuticals.

Millendo Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $29.00.

See today’s analyst top recommended stocks >>

Based on Millendo Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $11.63 million. In comparison, last year the company had a GAAP net loss of $5.68 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Millendo Therapeutics, Inc. is a biopharmaceutical company. The company is engaged in the development of novel treatments for endocrine diseases. Its products include livoletide and nevanimibe. The company was founded in April, 2011 and is headquartered in Ann Arbor, MI.